Cargando…

Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry

PURPOSE: For most disease sites, level 1 evidence is lacking for proton beam therapy (PBT). By identifying target populations that would benefit most from PBT, prospective registries could overcome many of the challenges in clinical trial enrollment. Herein, we report clinical outcomes of patients t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jongen, Aurélien, Charlier, Florian, Baker, Kelsey, Chang, John, Hartsell, William, Laramore, George, Mohindra, Pranshu, Moretti, Luigi, Redman, Mary, Rosen, Lane, Tsai, Henry, Van Gestel, Dirk, Vargas, Carlos, Rengan, Ramesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767257/
https://www.ncbi.nlm.nih.gov/pubmed/35071826
http://dx.doi.org/10.1016/j.adro.2021.100767
_version_ 1784634698163552256
author Jongen, Aurélien
Charlier, Florian
Baker, Kelsey
Chang, John
Hartsell, William
Laramore, George
Mohindra, Pranshu
Moretti, Luigi
Redman, Mary
Rosen, Lane
Tsai, Henry
Van Gestel, Dirk
Vargas, Carlos
Rengan, Ramesh
author_facet Jongen, Aurélien
Charlier, Florian
Baker, Kelsey
Chang, John
Hartsell, William
Laramore, George
Mohindra, Pranshu
Moretti, Luigi
Redman, Mary
Rosen, Lane
Tsai, Henry
Van Gestel, Dirk
Vargas, Carlos
Rengan, Ramesh
author_sort Jongen, Aurélien
collection PubMed
description PURPOSE: For most disease sites, level 1 evidence is lacking for proton beam therapy (PBT). By identifying target populations that would benefit most from PBT, prospective registries could overcome many of the challenges in clinical trial enrollment. Herein, we report clinical outcomes of patients treated with PBT for locally advanced non-small cell lung cancer (LA-NSCLC). METHODS AND MATERIALS: Data were obtained from the multi-institutional prospective database of the Proton Collaborative Group (PCG). Inclusion criteria of our study were stage III de novo or recurrent LA-NSCLC, use of PBT, and availability of follow-up data. Overall survival (OS) time was calculated from the start of treatment until death or last follow-up. Kaplan-Meier curves were generated for groups of interest and compared with log-rank tests. Cox regression modeling was used to evaluate the multivariate association between selected covariates and OS. RESULTS: A total of 195 patients were included in the analysis. PBT was given with a median equivalent dose in 2 Gy fractions (EQD2) of 63.8 Gy (relative biological effectiveness). Pencil beam scanning was used in 20% of treatments. Treatment-related grade 3 adverse events were rare: 1 pneumonitis, 2 dermatitis, and 3 esophagitis. No grade 4 events were reported. Two cardiac-related grade 5 events occurred in patients with multiple risk factors. The median follow-up time for living patients was 37.1 months and the median OS was 19.0 months. On multivariate analysis, good performance status (hazard ratio, 0.27; [95% confidence interval, 0.15-0.46]; P < .0001), pencil beam scanning use (0.55; [0.31-0.97]; P = .04), and increased EQD2 (0.80; [0.71-0.90] - per 10 Gy increase; P = .0002) were associated with decreased mortality. CONCLUSIONS: PBT appears to yield low rates of adverse events with an OS similar to other retrospective studies on PBT for LA-NSCLC. PBS use and increased EQD2 can potentially improve OS.
format Online
Article
Text
id pubmed-8767257
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87672572022-01-21 Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry Jongen, Aurélien Charlier, Florian Baker, Kelsey Chang, John Hartsell, William Laramore, George Mohindra, Pranshu Moretti, Luigi Redman, Mary Rosen, Lane Tsai, Henry Van Gestel, Dirk Vargas, Carlos Rengan, Ramesh Adv Radiat Oncol Scientific Article PURPOSE: For most disease sites, level 1 evidence is lacking for proton beam therapy (PBT). By identifying target populations that would benefit most from PBT, prospective registries could overcome many of the challenges in clinical trial enrollment. Herein, we report clinical outcomes of patients treated with PBT for locally advanced non-small cell lung cancer (LA-NSCLC). METHODS AND MATERIALS: Data were obtained from the multi-institutional prospective database of the Proton Collaborative Group (PCG). Inclusion criteria of our study were stage III de novo or recurrent LA-NSCLC, use of PBT, and availability of follow-up data. Overall survival (OS) time was calculated from the start of treatment until death or last follow-up. Kaplan-Meier curves were generated for groups of interest and compared with log-rank tests. Cox regression modeling was used to evaluate the multivariate association between selected covariates and OS. RESULTS: A total of 195 patients were included in the analysis. PBT was given with a median equivalent dose in 2 Gy fractions (EQD2) of 63.8 Gy (relative biological effectiveness). Pencil beam scanning was used in 20% of treatments. Treatment-related grade 3 adverse events were rare: 1 pneumonitis, 2 dermatitis, and 3 esophagitis. No grade 4 events were reported. Two cardiac-related grade 5 events occurred in patients with multiple risk factors. The median follow-up time for living patients was 37.1 months and the median OS was 19.0 months. On multivariate analysis, good performance status (hazard ratio, 0.27; [95% confidence interval, 0.15-0.46]; P < .0001), pencil beam scanning use (0.55; [0.31-0.97]; P = .04), and increased EQD2 (0.80; [0.71-0.90] - per 10 Gy increase; P = .0002) were associated with decreased mortality. CONCLUSIONS: PBT appears to yield low rates of adverse events with an OS similar to other retrospective studies on PBT for LA-NSCLC. PBS use and increased EQD2 can potentially improve OS. Elsevier 2021-09-10 /pmc/articles/PMC8767257/ /pubmed/35071826 http://dx.doi.org/10.1016/j.adro.2021.100767 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Scientific Article
Jongen, Aurélien
Charlier, Florian
Baker, Kelsey
Chang, John
Hartsell, William
Laramore, George
Mohindra, Pranshu
Moretti, Luigi
Redman, Mary
Rosen, Lane
Tsai, Henry
Van Gestel, Dirk
Vargas, Carlos
Rengan, Ramesh
Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry
title Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry
title_full Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry
title_fullStr Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry
title_full_unstemmed Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry
title_short Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry
title_sort clinical outcomes after proton beam therapy for locally advanced non-small cell lung cancer: analysis of a multi-institutional prospective registry
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767257/
https://www.ncbi.nlm.nih.gov/pubmed/35071826
http://dx.doi.org/10.1016/j.adro.2021.100767
work_keys_str_mv AT jongenaurelien clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT charlierflorian clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT bakerkelsey clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT changjohn clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT hartsellwilliam clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT laramoregeorge clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT mohindrapranshu clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT morettiluigi clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT redmanmary clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT rosenlane clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT tsaihenry clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT vangesteldirk clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT vargascarlos clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry
AT renganramesh clinicaloutcomesafterprotonbeamtherapyforlocallyadvancednonsmallcelllungcanceranalysisofamultiinstitutionalprospectiveregistry